Key Highlights:
- Biodeal Pharmaceuticals secured a ₹385 crore growth investment from RMB Capitalworks, a Rand Merchant Bank–Capitalworks Group joint venture, to expand its specialty pharma portfolio, manufacturing capabilities and presence across regulated markets.
- The investment will strengthen Biodeal’s nasal drug delivery leadership and accelerate expansion across Asia, CIS, LATAM, Africa and Europe, supported by its integrated drug development and manufacturing capabilities.
- Biodeal expects 60%+ YoY revenue growth in FY26, with further EBITDA margin expansion. The company plans to use its next growth phase to build a globally competitive specialty pharma platform and advance toward a planned public listing
Implications:
Biodeal’s ₹385 crore raise gives it the capital to scale up manufacturing, add new products, and enter more regulated markets, which should help it win bigger, longer-term contracts from global pharma companies. With 60%+ revenue growth in FY26 and a clear path toward an eventual IPO, the deal signals confidence in Biodeal’s niche (especially nasal drug delivery) and could encourage more investment in Indian CDMOs that can offer end-to-end development and manufacturing for complex formulations.
Source: ExpressPharma
